Open-label dose-escalation study of oral 1-octanol in patients with essential tremor

被引：38
|
作者：
Shill, HA
Bushara, KO
Mari, Z
Reich, M
Hallett, M
机构：
[1] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA
来源：
NEUROLOGY | 2004年 / 62卷 / 12期
关键词：
D O I：
10.1212/WNL.62.12.2320
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Twenty-one single oral doses of 1-octanol were given to patients with essential tremor ( ET) in an open-label dose-escalation study. The drug was well tolerated up to 64 mg/kg. The main side effect was an unusual taste. No overt intoxication was seen. There was evidence for efficacy, with a significant reduction in tremor amplitude as measured by accelerometry and handwriting that was maximal at 2 hours. Higher doses may produce more sustained benefit.
引用
收藏
页码：2320 / 2322
页数：3
相关论文
共 50 条
  • [41] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [42] Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
    Hong, D. S.
    Bauer, T. M.
    Lee, J. J.
    Dowlati, A.
    Brose, M. S.
    Farago, A. F.
    Taylor, M.
    Shaw, A. T.
    Montez, S.
    Meric-Bernstam, F.
    Smith, S.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Cox, M. C.
    Burris, H. A., III
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 325 - 331
  • [43] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.
    Anolik, JH
    Campbell, D
    Ritchlin, C
    Holyst, M
    Rosenfeld, S
    Sanz, I
    Young, F
    Felgar, R
    Kunkel, L
    Benyunes, M
    Grillo-Lopéz, A
    Rosenblatt, J
    Looney, RJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860
  • [44] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 53 - 53
  • [45] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Chris Twelves
    Alan Anthoney
    Claudio I. Savulsky
    Matthew Guo
    Larisa Reyderman
    Nicola Cresti
    Vladimir Semiglazov
    Constanta Timcheva
    Ishtiaq Zubairi
    Rosemary Morrison
    Ruth Plummer
    T. R. Jeffry Evans
    British Journal of Cancer, 2019, 120 : 579 - 586
  • [46] A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
    Twelves, Chris
    Anthoney, Alan
    Savulsky, Claudio, I
    Guo, Matthew
    Reyderman, Larisa
    Cresti, Nicola
    Semiglazov, Vladimir
    Timcheva, Constanta
    Zubairi, Ishtiaq
    Morrison, Rosemary
    Plummer, Ruth
    Evans, T. R. Jeffry
    BRITISH JOURNAL OF CANCER, 2019, 120 (06) : 579 - 586
  • [47] Ethosuximide for Essential Tremor: An Open-Label Trial
    Gironell, Alexandre
    Marin-Lahoz, Juan
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2016, 6
  • [48] Tiagabine for Essential Tremor: An Open-Label Trial
    Gironell, Alexandre
    Martinez-Corral, Merce
    Pagonabarraga, Javier
    Kulisevsky, Jaime
    MOVEMENT DISORDERS, 2008, 23 (13) : 1955 - 1956
  • [49] Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial
    Naik, Haley B.
    Pichard, Dominique C.
    Schwartz, Daniella M.
    O'Brien, Michelle
    Masciocchi, Matthew
    Thompson, Julie
    Sen, H. Nida
    Steinberg, Seth M.
    Mitchell, Sandra A.
    de Jesus, Adriana A.
    McCalmont, Timothy H.
    Dey, Amit
    Rosenstein, Rachel K.
    Deng, Zuoming
    Goldbach-Mansky, Raphaela
    Mehta, Nehal N.
    Cowen, Edward W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1380 - 1383
  • [50] Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Younes, Anas
    Connors, Joseph M.
    Park, Steven I.
    Fanale, Michelle
    O'Meara, Megan M.
    Hunder, Naomi N.
    Huebner, Dirk
    Ansell, Stephen M.
    LANCET ONCOLOGY, 2013, 14 (13): : 1348 - 1356
12345